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ABSTRACT 
Objective: This study aims to analyze the methyl hesperidin physicochemical properties related to solubility and permeability, and the affinity of 
methyl hesperidin against reverse transcriptase HIV-1 activity as a competitive substrate. 
Methods: This research was conducted using the computerized method, ChemOffice 15.0, to predict ligand physicochemical properties related to 
solubility and permeability, and Autodock Vina with Autodock Tools program to analyze ligand-receptor affinity. 
Results: The analysis result of physicochemical properties of hesperidin and methyl hesperidin is respectively 300,27 g/Mol, 1,78, and 314,29 
g/Mol, 2,04. The docking result shows that the binding energy of hesperidin, methyl hesperidin and zidovudine with receptor are respectively-8,0,-
8,8 and-9,3 kcal/Mol. The type of interactions between receptor and hesperidin is van der Waals and phi-phi staked, methyl hesperidin are van der 
Waals, hydrogen bond, phi-sigma, and phi-phi stacked, and zidovudine is an attractive charge, hydrogen bond, and phi-sigma.  
Conclusion: Methyl hesperidin has good solubility and permeability, and has affinity with the receptor, a substrate of reverse transcriptase HIV-1.  
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Acquired immunodeficiency syndrome (AIDS) is a global and deadly 
disease in the world. Based on the global report of the World Health 
Organization (WHO), the amount of death in the world caused by AIDS 
reached 1,8 million people [9]. Based on the data from the Health 
Ministry of Republic Indonesia, the incident number of AIDS in 
September 2014 reached 55.799 people in Indonesia [8]. Drug therapy 
for AIDS known as Retroviral Drug now has resistance and side effect 
problems affecting medication [10, 16, 21]. Therefore, there is a 
necessary to discover a new agent as anti-HIV. Nature is a source for 
anti-HIV because the drug discovery is begun from a plant [11].  
Orange plant, one of a typical Kalimantan Barat plant, has a potential 
to be developed into antiHIV because this plant produces a few 
secondary metabolites such as hesperidin, tangeritin, hesperitin, 
naringin and naringenin. Hesperidin has been proved as 
antidiabetic, anticholesterol, antiinflammation, antioxidant and 
antifertility [6]. There are no toxic effects found in the trial of male 
and female mice. Moreover, hesperidin could be easily digested and 
is not accumulated in the body and hesperidin also does not cause an 
allergic reaction [5]. In another trial, 70% ethanol extract of Justicia 
gendarussa Burm. f leaves had been proved to inhibit the activity of 
reverse transcriptase HIV-1 and apigenin is the main secondary 
metabolite detected in the extract [4]. Apigenin had also been 
proved to inhibit the activity of reverse transcriptase HIV-1 as a 
competitive substrate, in vitro [3]. Hesperidin has a similar chemical 
structure with apigenin. They are flavonoid that has three rings with 
same chemical structures. Based on these data, hesperidin could 
possibly inhibit the activity of reverse transcriptase HIV-1. 
Reverse transcriptase has an important role in the HIV life cycle 
because of the enzyme reversely transcript ribonucleic acid (RNA) 
virus into deoxyribonucleic acid (DNA) virus. DNA of virus next is 
incorporated into the DNA of the host cell and when host cell 
transcripts the code area containing this DNA, proteins needed to 
create a new virus are produced. All of those proteins and enzymes 
needed to create a new virus are originated from the host cell. Only 
reverse transcriptase, integrase and virus RNA are originally 
brought by the virus [7]. Therefore, the inhibition of the activity of 
reverse transcriptase HIV-1 could stop virus replication. 
Although hesperidin has a potency as an anti-HIV activity, hesperidin 
could not be absorbed well in the body. Solubility, one of the 
physicochemical properties of hesperidin is low in the body causing 
low bioavailability. The solubility in water, stomach and intestine are 
respectively 57 mg/l, 49,1 mg/l and 68,0 mg/l [2]. Log P of hesperidin 
are 0,30 [1]. Therefore, there is a necessary to improve the solubility of 
hesperidin. Chemical structure modification is a way to improve 
hesperidin solubility by methyl addition, a nonpolar functional group, 
into hesperidin chemical structure and also eliminates the glicon 
functional group from the structure.  
It is needed to analyze that the addition of methyl into the chemical 
structure does not change the anti-HIV activity of hesperidin. The one of 
research methods could be chosen is a computerized method. The 
method could predict the solubility and the affinity of interaction 
between ligand and receptor. This study aims to analyze the 
physicochemical properties related to hesperidin solubility and 
permeability properties in the body and the docking study of methylated 
hesperidin as a competitive substrate of reverse transcriptase HIV-1. 
MATERIALS AND METHODS 
Materials 
Hardware used for physicochemical property analysis and docking study 
of ligand is Notebook PC ASUS X455L Series with the specifications of 
Intel Core i3-4030U CPU 1,90 GHz, system operation Windows 8,1 
Enterprise with 64-bit windows and 2,00 GB of RAM. Software used for 
physicochemical property analysis of ligand is ChemDraw 15.0. Software 
used for docking study of ligand is Autodock Vina with Autodock Tools 
1.1.2 version and software used for docking visualization of ligand-
receptor interaction is Discovery Studio. 
Docking methodology 
2 dimensions (2D) and 3 (3D) dimensions, the chemical structure of 
ligand was obtained by drawing ligand structure and setting the 
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minimal sterical energy of ligand structure. Receptor, reverse 
transcriptase HIV-1 substrate, was downloaded from RCSB Protein 
Data Bank (http://www.rcsb.org/pdb/home/home.do). Grid 
parameter was set using Autodock Tools to coordinate-18.177 x 25.99 
x 37.741 A (Amstrong) and dimension 30 x 30 x 30 A. Grid dimension 
was set same between the ligand and positive control. Docking study 
was calculated using Autodock Vina with the grid parameter and type 
of interaction was visualized using Discovery Studio.  
The analysis of physicochemical properties 
Physicochemical properties of ligand were analyzed using Chem 
Draw 15.0 [12]. 
Data analysis 
The analysis result of ligand physicochemical properties (LogP, BM, 
H H acceptor and donor) are analyzed using the rule of five Lipinski 
to predict the properties of ligand absorption and permeability. The 
affinity of ligand-receptor interaction was analyzed using Autodock 
Vina and Discovery Studio to analyze ligand-receptor binding energy 
and amino acid residues involved from ligand-receptor interaction 
(kcal/Mol) [18-20]. 
RESULTS AND DISCUSSION 
Chemical structure of modification is a part of drug development. 
Addition of functional group of atoms in the chemical structure of a 
compound would change the polarity and affinity of a compound to a 
receptor [12]. In order to certain, the effect of methyl addition into 
hesperidin against the solubility and the affinity of methyl 
hesperidin to the receptor, physicochemical property analysis and 
docking study was conducted in this research based on a very large 
mathematical operation in computational chemistry. The method 
integrates chemical theory and modelling with experimental 
observations based on mathematical algorithms, statistics and 
databases. It calculates the fundamental laws of physic of an atom 
such as charged particles, positive nuclei, negative electrons and 
geometrical arrangements of the nuclei correspond to stable 
molecules, and how atoms interact each other. Therefore, this 
method could contribute as preliminary studies for supporting in 
vitro and in vivo experimental method [18].  
3D chemical structures of hesperidin, methyl hesperidin and 
(positive control) zidovudine obtained using ChemDraw and after 
minimizing energy are shown in fig. 1. 
  
 
Fig. 1: Ligand 3D structure obtained using ChemDraw 15.0, A): Hesperidin, B): methyl hesperidin, C): zidovudine 
 
Minimizing the energy of ligand structure obtained using Chem 
Office program is conducted to obtain the most stable conformation 
of the ligand that are close to the real ligand binding to the receptor 
in the human body. In order to obtain the confirmation of a 
compound that is as similar as the one in the nature, the minimizing 
energy would give the best arrangement of atoms position in a space 
for a compound so net inter-atomic force and sterical energy of each 
atom are close to zero and the position on the potential energy 
surface is a stationary point. The confirmation of structure would 
affect the real physicochemical properties of a compound. It also 
affects the docking score showing the affinity of ligand-receptor [13].  
The analysis result of ligand physicochemical properties showed 
that log P of methyl hesperidin is more than hesperidin. Same as 
hesperidin, methyl hesperidin have a molecular weight less than 500 
and C log P is less than 5. The amount of N-H functional group for 
Amida are 0, and O-H functional group for carboxylate and phenol 
are 2, the total are 2, means less than 5. The amount of O atom is 5 
and N atom are 0, so the total are 5, means less than 10. According to 
Lapinski Rule, these could be predicted that hesperidin and methyl 
hesperidin could be absorbed and has good permeability.  
Lapinski Rule reveals that a drug would be pharmacology active if it 
has physicochemical properties contributing to drug pharmaco-
kinetics in the human body including absorption, distribution, 
metabolism and excretion. This rule proved based on empirically 
screening program for the most oral drug that a range of physical 
properties is consistent with oral activity such as Acyclovir, 
Alprazolam, Proxicam, Vinblastin and 2000 others. In general, a drug 
has low absorption and permeability because the molecular weight 
is more than 500 Dalton, an octanol-water partition of coefficient log 
P is greater than 5, hydrogen bond acceptors of a drug are more than 
10 for nitrogen or oxygen atoms, and hydrogen bond donors for a 
drug are more than 5 for nitrogen or oxygen atoms with one or more 
hydrogen atoms [12].  
Both ligand, methyl hesperidin, hesperidin and positive control were 
optimized using Autodock Tools to determine various factors 
contributing to ligand affinity to receptors such as partial charges, 
the addition of both polar and nonpolar hydrogen atoms, rotatable 
bonds, the number of torsional degrees, identifying an atom as a 
central root and the torsion count.  
Crystal structure of the receptor was downloaded from RCSB 
Protein Data Bank (http://www.rcsb.org/pdb/home/home.do), in 
the form of reverse transcriptase HIV-1 complex with DNA and 
zidovudine, with the code of receptor 3V4I. The receptor was 
optimized using Autodock Tools such as eliminating water, adding 
hydrogen atoms and partial charges. 
Grid parameters for methyl hesperidin and hesperidin were set 
close to positive control grid box by choosing the similar dimension 
area. It was conducted in order to keep the docking result is in the 
active site of the receptor. The active site of receptor chosen are 
amino acid residues affecting the function or activity of the enzyme.  
The binding energy score for methyl hesperidin are different 0.8 
kcal/mole than hesperidin binding energy score as shown in table 1. 
The binding energy score of hesperidin and methyl hesperidin, and 
positive control, zidovudine are lower than zero. This means that the 
binding of ligand and receptor cause releasing energy called 
exoterm. Binding energy shows the inter-atomic force, the sterical 
energy and potential energy resulted from ligand-receptor binding. 
The lower energy binding score from ligand-receptor binding, the 
more stable the ligand-receptor to bind. This because the better 
affinity of ligand-receptor is determined by the stability of ligand-
receptor binding[13]. The RMSD score shows the iteration of 
conformation model of ligand that could bind to receptor with the 
binding energy score shown in table 1 is significantly not different 
[15]. It could be predicted that methyl hesperidin, hesperidin could 
be bound to the receptor as positive control. 
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Table 1: Binding energy and binding site obtained using autodock vina 1.1.2. 
Ligand Binding energy score (kcal/Mol) RMSD 
Hesperidin -8.0 0,000 
Methyl Hesperidin -8.8 0,000 
Zidovudine -9,3 0,000 
 
Hesperidin, methyl hesperidin and Zidovudin could inhibit the activity of 
the enzyme, reverse transcriptase. This could be proved first by 
comparing the hesperidin and methyl hesperidin binding energy score 
with a proven antiretroviral drug, Zidovudin. Second, the relationship 
between binding energy score with the bioactivity of the drug is shown 
in a docking study of Glimepirid and Glibenclamid, antidiabetic drugs 
with the binding energy score that is lower than zero [19]. Moreover, 
another study shows the relationship between the binding energy score 
with bioactivity study. A compound in Buddleja salviifolia (L). Lam leaf 
showed the binding energy score is lower than zero and has bioactivity 
as anti-inflammatory and antioxidant [20].  
Type of interaction between ligand, hesperidin and receptor, DNA, 
using Discovery Studio is shown in fig. 2. 
Type of interaction between ligand, methyl hesperidin and receptor, 
DNA, using Discovery Studio is shown in fig. 3. 
 
  
Fig. 2: Visualization of hesperidin-receptor interaction using discovery studio, A): Type of interaction between hesperidin and receptor, 
B): Hesperidin is in the position of the receptor substrate 
 
  
Fig. 3: Visualization of methyl hesperidin-receptor interaction using discovery studio, A): Type of interaction between methyl hesperidin 
and receptor, B): Methyl hesperidin is in the position of the receptor substrate 
 
Type of interaction between methyl hesperidin and receptor is more 
than hesperidin and the receptor as shown in fig. 2 and 3. This 
contributes to the different binding energy score between both 
ligands. Both ligands could be bound in the active site of the 
substrate position of receptor shown in fig. 2 and 3. Because both 
ligands have no atoms that could facilitate phosphate bond to the 
next incoming substrate, both ligands could act as stop codon for 
reverse transcription of virus RNA into DNA [14].  
Type of interaction between positive control, zidovudine, and DNA 
using Discovery Studio are shown in fig. 4. Zidovudine has the 
most interactions contributing to the greatest zidovudine binding 
energy score. Zidovudine could be bound in the substrate position 
of the receptor. Because zidovudine has no atoms that could 
facilitate phosphate bond to the next incoming substrate, 
zidovudine could act as stop codon for reverse transcription of 
virus RNA into DNA [14]. 
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Fig. 4: Visualization of zidovudine-receptor interaction using discovery studio, A): Type of interaction between zidovudine and receptor, 
B): Zidovudine is in the position of the receptor substrate 
 
Hesperidin and methyl hesperidin could inhibit the activity of 
reverse transcriptase because of both ligand bind to an amino acid 
residue in the active site of the substrate. There is a relationship 
between the binding sites of docking studies with the bioactivity of 
the drug. In a study of proven antidiabetic drugs showed that 
Glimepiride bind to the different kind of amino acid residue with 
other antidiabetic drug but both ligand has good bioactivity [19]. In 
other studies showed that there is a relationship between docking 
studies and the bioactivity of the compound in Buddleja salviifolia 
(L). Lam leaf {20], and the consistent result between docking result 
and in vitro antibacterial of N-[(2-chloroquinolin-3-yl) methylidene]-
2-aniline [17]. This relationship could be obtained because the 
different kind of amino acid residue is located in the active site of 
receptor whose receptor activity.  
In order to obtain the information about the methyl hesperidin 
activity as anti-HIV, especially related to the quantity of 
compound that could inhibit the activity of reverse transcriptase, 
we need to conduct a research experiment. Computational 
chemistry is a qualitative method used to determine whether or 
not atoms of a ligand interaction with atoms of a receptor. The 
method was conducted only based on the calculation of 
theoretical approach [18].  
CONCLUSION 
The results first showed that according to Lapinski Rule, methyl 
hesperidin has physicochemical properties contributing to drug 
pharmacokinetics in the human body. It could be predicted that 
methyl hesperidin would be pharmacology active. The second 
showed that the binding energy of methyl hesperidin is lower than 
zero, as zidovudine, a proven antiretroviral drug. It means that 
methyl hesperidin could be bound to reverse transcriptase as 
competitive substrate. Therefore, It could be predicted that methyl 
hesperidin could be absorbed and penetrated into the human body, 
and could inhibit the activity of reverse transcriptase HIV-1.  
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